Can We Actually Regrow Cartilage? My Honest Read on the Stanford Study
A Science study regrew true hyaline cartilage in older mice by blocking an aging enzyme. What it found, what it doesn't show, and whether you should wait for it.
A patient came into my Renton office recently — early sixties, active, medial compartment worn down to almost bone-on-bone on his X-ray. Before I could start my usual conversation about activity modification, injections, and eventually a partial knee replacement, he pulled out his phone and showed me a headline: scientists had regrown cartilage and might make knee replacements obsolete. "Should I just wait for this?"
I have had a version of that conversation a dozen times since. Here is the thing — the study behind those headlines is real, it was published in Science, and it is the most interesting cartilage research I have read in years. It also does not mean what the headlines say it means. Both are true at once, and I would rather you hear the honest version from me than from a clinic that wants to sell you an injection today.1
What the study actually found
A team at Stanford focused on an enzyme called 15-PGDH. Think of it as a brake pedal on your body's own repair signaling — it breaks down a molecule (prostaglandin E2) that helps tissue regenerate. As we age, the amount of 15-PGDH in cartilage roughly doubles. More brake, less repair.
They gave older mice a drug that blocks that enzyme, either body-wide or injected directly into the knee. The worn cartilage grew back thicker — and, more importantly to me, it grew back as hyaline cartilage, the smooth load-bearing kind, not the scar-like fibrocartilage most of our current cartilage procedures produce.
Then they did something that got my attention as a sports surgeon: they used a mouse model that mimics an ACL tear. Mice treated for four weeks after the injury were far less likely to develop arthritis, and walked more normally on the injured leg. Finally, they took human cartilage removed during knee replacement surgery, treated it for a week, and saw fewer cartilage-destroying cells and the beginnings of new articular cartilage.1
Why this is different from the usual cartilage hype
I am skeptical by default about anything marketed as regenerative. I have watched stem cell clinics, PRP, and amniotic injections cycle through with big promises and thin data. Most of what those treatments do, when they do anything, is reduce inflammation for a while. None of them reliably rebuild a joint surface.
This mechanism is different. There are no stem cells involved at all — the cartilage cells already living in your knee change which genes they express and start behaving like younger cells again. In the mouse data, the population building healthy cartilage nearly doubled while the population chewing it up dropped by more than half. That is a described biological mechanism in a top-tier journal, not a claim on a clinic website.1
What it does not show — and this part matters
- Mice are not people. Aged mouse cartilage thinning is not the same problem as a human knee with thirty years of wear, bone spurs, cysts, a missing meniscus, and a bowed leg.
- The human piece was tissue in a dish for one week — not a patient walking on a knee.
- No human cartilage trial has started. An oral version cleared a Phase 1 safety study in healthy volunteers, but that trial was for age-related muscle weakness, not joints.
- Regrowing cartilage does not fix alignment. If your leg is bowed, new cartilage in that compartment faces the same overload the old cartilage did.
- The realistic estimate from people close to the work is five to ten years, if everything goes well. Most things in this space do not.
Where cartilage treatment actually stands right now
| Option | What it realistically does | Who it fits |
|---|---|---|
| Injections (cortisone, hyaluronic acid) | Reduces pain and inflammation; does not rebuild cartilage | Buying time, managing flares |
| Microfracture | Fills a small defect with fibrocartilage — durable for a few years | Small defects, lower-demand knees |
| MACI (cell-based cartilage graft) | Builds cartilage-like tissue in a contained defect | Younger patients, single focal defect |
| Osteochondral allograft (OCA) | Transplants real hyaline cartilage with its bone base | Larger defects, young active patients |
| Partial knee replacement | Resurfaces one worn compartment; keeps ligaments | Arthritis limited to one compartment |
| Total knee replacement | Resurfaces the whole joint; the most reliable pain relief we have | Diffuse, end-stage arthritis |
| 15-PGDH inhibitor (research) | Potentially regrows true hyaline cartilage — unproven in patients | Nobody yet; watch this space |
Who I talk to about this in clinic
Cartilage injury and arthritis is a daily conversation in clinic. This topic comes up in these common scenarios:
- Young athletes with a single focal cartilage defect. The group I am most hopeful for long term. Today the answer is still MACI or an osteochondral graft — those work reasonably well, but they are big operations for a small patch of damage.
- My ACL patients. The arthritis-prevention finding excites me more than the regrowth finding. Roughly half of people who tear an ACL develop arthritis in that knee over the following decade and a half, and I have nothing to offer for that today besides good surgery and good rehab.2
- Patients in their forties and fifties with moderate arthritis who are genuinely too young for a replacement. If this works, they probably benefit first.
- Patients with end-stage arthritis asking whether to wait. My honest answer is no. Do not spend five to ten more years in pain, losing muscle and mobility, betting on a drug that has not entered a joint trial.
Frequently asked questions
Should I delay my knee replacement to wait for this?
No. The drug has not entered a human joint trial, and even the optimistic estimate is five to ten years out. Waiting in pain means lost muscle, lost activity, and sometimes a harder operation later. If you are on the fence about timing for other reasons, that is a real conversation — but this study should not be the deciding factor.
Is this the same as the stem cell injections advertised around Seattle?
No, and this matters. Those clinics use PRP, bone marrow concentrate, or amniotic products. This is a small-molecule drug that blocks an enzyme, and it works without stem cells at all. It is not for sale anywhere. Anyone citing cartilage regeneration research to sell you an injection is borrowing credibility they have not earned.
Would this have helped my knee after my ACL reconstruction?
Possibly — this is the part I am watching most closely. In the mouse ACL model, four weeks of treatment after injury substantially reduced arthritis. Right now I can restore your stability, but I cannot promise you a normal joint surface in twenty years.
What can I actually do for my cartilage right now?
The unglamorous answers are still the best: keep the quadriceps and hips strong, keep your weight in a healthy range since every pound is multiplied several times across the knee, stay active with lower-impact loading, and do not live on an unstable knee. Delays after an ACL tear measurably increase secondary meniscus and cartilage damage.
How will I know if this becomes real?
Watch for a Phase 2 trial in knee osteoarthritis with real imaging and symptom outcomes. That is the milestone that moves this from interesting biology to plausible treatment. Ask me at any visit and I will tell you where it stands.
The bottom line
I want this to work. I do a lot of knee replacements — ranked among the top ten nationally by volume by U.S. News — and I helped design a partial knee implant. I would happily do fewer of them if a drug let people keep their own joint. That is the goal. We are not there.
So bring me the headline. Seriously. I would much rather spend ten minutes of your visit on what a study does and does not show than have you quietly delay care you need, or spend thousands on a treatment borrowing a real study's credibility. Bring the phone, bring the article, and let's talk about your actual knee.
References
- Singla M, Wang YX, Monti E, Bedi Y, Agarwal P, Su S, Ancel S, Hermsmeier M, Devisetti N, Pandey A, Bakooshli MA, Palla AR, Goodman S, Blau HM, Bhutani N. Inhibition of 15-hydroxy prostaglandin dehydrogenase promotes cartilage regeneration. Science. 2026;391(6789):eadx6649. doi:10.1126/science.adx6649
- Lohmander LS, Englund PM, Dahl LL, Roos EM. The long-term consequence of anterior cruciate ligament and meniscus injuries: osteoarthritis. Am J Sports Med. 2007;35(10):1756-1769. doi:10.1177/0363546507307396
This article is general education, not medical advice for your situation. Every knee and hip is different — talk with your own doctor about your care.